دورية أكاديمية
Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
| العنوان: | Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. |
|---|---|
| المؤلفون: | DeNardo SJ; University of California at Davis, Sacramento, California, USA., Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 1997 Aug; Vol. 38 (8), pp. 1180-5. |
| نوع المنشور: | Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print Cited Medium: Print ISSN: 0161-5505 (Print) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
| مواضيع طبية MeSH: | Radioimmunotherapy*, Breast Neoplasms/*radiotherapy , Indium Radioisotopes/*therapeutic use , Yttrium Radioisotopes/*therapeutic use, Chelating Agents/therapeutic use ; Female ; Humans ; Middle Aged ; Pentetic Acid/analogs & derivatives ; Pentetic Acid/therapeutic use ; Radiotherapy Dosage |
| مستخلص: | Unlabelled: BrE-3 is a murine IgG1 monoclonal antibody that binds to 97% of human ductal breast cancer specimens. A previous study documented the ability of 111In-labeled 1,4-methyl-benzyl isothiocyanate diethylenetriamine pentaacetic acid (111In-MX-DTPA) BrE-3 to specifically target breast cancer tissue in patients, and the dosimetry derived from the pharmacokinetics suggested that a useful therapeutic index could be obtained with 90Y-MX-DTPA BrE-3. A Phase I maximum tolerated dose study was, therefore, initiated. Methods: Six patients received 111In/90Y-MX-DTPA BrE-3, three of them receiving 6.25 and the other three receiving 9.25 mCi/m2 of 90Y. Pharmacokinetics, dosimetry, human anti-mouse antibody (HAMA), toxicity and clinical responses were evaluated. Results: Three of six patients demonstrated a minor and transient, but objective tumor response, and none of the patients had significant toxicity. Tumor dosimetry ranged from 39 to 167 rad/mCi of 90Y (442-1887 rad/ dose). HAMA response occurred in five of six patients. Conclusion: Minimal toxicity, dosimetric calculations and clinical assessment indicate that a useful therapeutic index can be achieved with this therapy. Indium-111/yttrium-90-MX-DTPA BrE-3 can be safely administered to patients with metastatic breast cancer, and therapy doses yielded pharmacokinetics similar to those of tracer doses. Clinical responses, albeit transient, were achieved with single-dose therapy. Rapid onset of the HAMA response will hinder multicycle therapy, unless it is prevented with immunosuppressive drugs or the use of a "humanized" antibody. Further studies are needed to determine the optimal use of BrE-3 for radioimmunotherapy. |
| معلومات مُعتمدة: | 3PO1-CA42767 United States CA NCI NIH HHS; CA47829 United States CA NCI NIH HHS; R01-CA39932 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Chelating Agents) 0 (Indium Radioisotopes) 0 (Yttrium Radioisotopes) 141849-44-7 (2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid) 7A314HQM0I (Pentetic Acid) |
| تواريخ الأحداث: | Date Created: 19970801 Date Completed: 19970908 Latest Revision: 20131121 |
| رمز التحديث: | 20221213 |
| PMID: | 9255145 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0161-5505 |
|---|